Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 + Standard of Care in Relapsed/Refractory Multiple Myeloma
NCT06622005Phase 1Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SX-682 in multiple myeloma (MM), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Apr 2025; status: recruiting.
02
Drugs
SX-682
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06622005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622005.